Y-mAbs is a commercial-stage biopharmaceutical company focused on antibody-based cancer immunotherapy, primarily serving the pediatric oncology market. The company's sole commercial product, DANYELZA (naxitamab), is an FDA-approved monoclonal antibody targeting GD2, a molecule expressed on certain tumor cells. DANYELZA is approved for relapsed or refractory high-risk neuroblastoma — a rare pediatric cancer — in the bone or bone marrow. A key practical advantage is its short infusion time of roughly 30–60 minutes administered in an outpatient setting, compared to the 10–20 hour infusions required by its primary competitor, Unituxin. Y-mAbs sells DANYELZA in the U.S. directly through a lean commercial team targeting roughly 70 specialized pediatric cancer centers. Internationally, Y-mAbs licenses or distributes through regional partners across Greater China, Latin America, Europe, Japan, and the Middle East, generating product sales, milestone payments, and profit-sharing revenue. Beyond DANYELZA, Y-mAbs is investing in a radiopharmaceutical platform called SADA PRIT, which separates the antibody and radioactive payload into two sequential injections. This approach aims to concentrate radiation at the tumor while reducing exposure to healthy tissue, and allows treatment to be partially delivered in standard infusion centers. Y-mAbs has two SADA constructs in Phase 1 trials: one targeting GD2-positive solid tumors and one targeting CD38-positive Non-Hodgkin Lymphoma. Y-mAbs does not own manufacturing facilities and relies on contract manufacturers.